229 related articles for article (PubMed ID: 36761738)
1. Kinetics of SARS-CoV-2 neutralizing antibodies in Omicron breakthrough cases with inactivated vaccination: Role in inferring the history and duration of infection.
Simayi A; Li C; Chen C; Wang Y; Dong C; Tian H; Kong X; Zhou L; Peng J; Zhang S; Zhu F; Hu J; Xu K; Jin H; Fan H; Bao C; Zhu L
Front Immunol; 2023; 14():1083523. PubMed ID: 36761738
[TBL] [Abstract][Full Text] [Related]
2. Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort.
Zhu L; Mao N; Yi C; Simayi A; Feng J; Feng Y; He M; Ding S; Wang Y; Wang Y; Wei M; Hong J; Li C; Tian H; Zhou L; Peng J; Zhang S; Song C; Jin H; Zhu F; Xu W; Zhao J; Bao C
Emerg Microbes Infect; 2023 Dec; 12(1):2146535. PubMed ID: 36373485
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines.
Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X
Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897
[TBL] [Abstract][Full Text] [Related]
4. Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.
Zhang S; Dong C; Zhen Q; Shi C; Tian H; Li C; Kong X; Dai Q; Huang H; Simayi A; Zhu F; Xu Y; Hu J; Xu K; Chen L; Bao C; Jin H; Zhu L
Microbiol Spectr; 2023 Aug; 11(4):e0180823. PubMed ID: 37432106
[TBL] [Abstract][Full Text] [Related]
5. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
6. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
7. Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2.
Yamamoto S; Matsuda K; Maeda K; Oshiro Y; Inamura N; Mizoue T; Konishi M; Takeuchi JS; Horii K; Ozeki M; Sugiyama H; Mitsuya H; Sugiura W; Ohmagari N
BMC Infect Dis; 2023 May; 23(1):282. PubMed ID: 37142992
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
[TBL] [Abstract][Full Text] [Related]
9. Duration of BA.5 neutralization in sera and nasal swabs from SARS-CoV-2 vaccinated individuals, with or without omicron breakthrough infection.
Planas D; Staropoli I; Porot F; Guivel-Benhassine F; Handala L; Prot M; Bolland WH; Puech J; Péré H; Veyer D; Sève A; Simon-Lorière E; Bruel T; Prazuck T; Stefic K; Hocqueloux L; Schwartz O
Med; 2022 Dec; 3(12):838-847.e3. PubMed ID: 36228619
[TBL] [Abstract][Full Text] [Related]
10. Plaque-neutralizing antibody to BA.2.12.1, BA.4 and BA.5 in individuals with three doses of BioNTech or CoronaVac vaccines, natural infection and breakthrough infection.
Cheng SS; Mok CK; Li JK; Ng SS; Lam BH; Jeevan T; Kandeil A; Pekosz A; Chan KC; Tsang LC; Ko FW; Chen C; Yiu K; Luk LL; Chan KK; Webby RJ; Poon LL; Hui DS; Peiris M
J Clin Virol; 2022 Nov; 156():105273. PubMed ID: 36081282
[TBL] [Abstract][Full Text] [Related]
11. Omicron BA.1 breakthrough infections in inactivated COVID-19 vaccine recipients induced distinct pattern of antibody and T cell responses to different Omicron sublineages.
Guo L; Zhang Q; Zhong J; Chen L; Jiang W; Huang T; Li Y; Zhang Y; Xu L; Wang X; Xiao Y; Wang Y; Dong X; Dong T; Peng Y; Zhang B; Xie Y; Gao H; Shen Z; Ren L; Cheng T; Wang J
Emerg Microbes Infect; 2023 Dec; 12(1):2202263. PubMed ID: 37037791
[TBL] [Abstract][Full Text] [Related]
12. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn.
Munoz FM; Posavad CM; Richardson BA; Badell ML; Bunge KE; Mulligan MJ; Parameswaran L; Kelly CW; Olson-Chen C; Novak RM; Brady RC; Pasetti MF; Defranco EA; Gerber JS; Shriver MC; Suthar MS; Coler RN; Berube BJ; Kim SH; Piper JM; Miller AM; Cardemil CV; Neuzil KM; Beigi RH;
Vaccine; 2023 Aug; 41(36):5296-5303. PubMed ID: 37451878
[TBL] [Abstract][Full Text] [Related]
13. Immune responses in COVID-19 patients during breakthrough infection with SARS-CoV-2 variants Delta, Omicron-BA.1 and Omicron-BA.5.
Bormann M; Brochhagen L; Alt M; Otte M; Thümmler L; van de Sand L; Kraiselburd I; Thomas A; Gosch J; Braß P; Ciesek S; Widera M; Dolff S; Dittmer U; Witzke O; Meyer F; Lindemann M; Schönfeld A; Rohn H; Krawczyk A
Front Immunol; 2023; 14():1150667. PubMed ID: 37520539
[TBL] [Abstract][Full Text] [Related]
14. The serological IgG and neutralizing antibody of SARS-CoV-2 omicron variant reinfection in Jiangsu Province, China.
Chu J; Dai Q; Dong C; Kong X; Tian H; Li C; Peng J; Xu K; Ju H; Bao C; Hu J; Zhu L
Front Public Health; 2024; 12():1364048. PubMed ID: 38873290
[TBL] [Abstract][Full Text] [Related]
15. Distinct features of SARS-CoV-2 humoral immunity against Omicron breakthrough infection.
Goto T; Chong Y; Tani N; Susai N; Yoshinaga T; Sasaki T; Taniguchi M; Kusakabe T; Shimono N; Akashi K; Ikematsu H
Vaccine; 2023 Nov; 41(47):7019-7025. PubMed ID: 37858449
[TBL] [Abstract][Full Text] [Related]
16. Neutralizing Antibody Responses against Five SARS-CoV-2 Variants and T Lymphocyte Change after Vaccine Breakthrough Infections from the SARS-CoV-2 Omicron BA.1 Variant in Tianjin, China: A Prospective Study.
Zhang Y; Qu JW; Zheng MN; Ding YX; Chen W; Ye SD; Li XY; Li YK; Liu Y; Zhu D; Jin CR; Wang L; Yang JY; Zhai Y; Wang EQ; Meng X
Biomed Environ Sci; 2023 Jul; 36(7):614-624. PubMed ID: 37533385
[TBL] [Abstract][Full Text] [Related]
17. Ad5-nCoV booster and Omicron variant breakthrough infection following two doses of inactivated vaccine elicit comparable antibody levels against Omicron variants.
Kong W; Zhong Q; Chen M; Yu P; Xu R; Zhang L; Lai C; Deng M; Zhou Q; Xiong S; Liang Y; Wan L; Lin M; Wang M; Mai W; Chen L; Lei Y; Qin N; Zhu J; Ruan J; Huang Q; Kang A; Wang J; Li W; Ji T
J Med Virol; 2023 Jan; 95(1):e28163. PubMed ID: 36127294
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.
Franchini M; Focosi D; Mengoli C; Percivalle E; Sammartino JC; Ferrari A; Zani M; Glingani C; Baldanti F
Transfusion; 2022 Jun; 62(6):1171-1176. PubMed ID: 35426131
[TBL] [Abstract][Full Text] [Related]
19. Durability of neutralization against Omicron subvariants after vaccination and breakthrough infection.
Zhu KL; Jiang XL; Zhan BD; Wang XJ; Xia X; Cao GP; Sun WK; Huang PX; Zhang JZ; Gao YL; Dai EH; Gao HX; Ma MJ
Cell Rep; 2023 Feb; 42(2):112075. PubMed ID: 36774551
[TBL] [Abstract][Full Text] [Related]
20. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
Miyamoto S; Suzuki T
Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
